期刊文献+

阿托伐他汀对人脐静脉内皮细胞增殖活性的影响

Effect of atorvastatin on the human umbilical vein cells
暂未订购
导出
摘要 目的观察阿托伐他汀对人脐静脉内皮细胞增殖(humanumbilicalveinendothelialcells,HUVEC)及超微结构的影响。方法将HUVEC分为3组进行培养,包括正常对照组、重组人白细胞介素6(rhIL6)刺激组和阿托伐他汀组。通过MTT法测定各组细胞的增殖活力,并用透射电镜观察各组细胞超微结构的改变。结果①正常对照组、rhIL6组及阿托伐他汀组的吸光度(A)分别为0.172±0.014、0.257±0.058及0.184±0.021;②rhIL6作用下,HUVEC粗面内质网上核糖体较对照组明显增多,而阿托伐他汀可抑制rhIL6对HUVEC的这种超微结构改变。结论阿托伐他汀能有效抑制rhIL6,进而阻止HUVEC增殖。 ObjecUve To study the effect of atorvastatin on proliferation and uhrastructure of HUVEC which was induced by rhIL-6. Methods In vitro, HUVEC was cultured and divided into three groups. Group 1 served as controls. Group 2 was given 10 ng/ml rhIL-6. Group 3 was given 10 ng/ml rhIL- 6 ± 10μ mol/Latorvastatin. The changes of proliferous activity and uhrastructure of HUVEC were observed by MTT and transmission electromicroscope. Results ① Compared with the control group, rhIL-6 accelerated the proliferation of HUVEC while the atorvastatin restrained it. The difference was significant.② Compared with the control group, rhIL-6 could increase the amount of ribosomes on rough endoplasmic reticulum, Compared with the rhIL-6 group, atorvastatin reduced the amount of ribosomes. Conclusion Atorvastatin may restrain the effect of cytokines and prevent the proliferation of HUVEC. Along with that effect, the number of ribosomes on rough endoplasmic reticulum was decreased too.
出处 《中国脑血管病杂志》 CAS 2006年第5期201-203,210,共4页 Chinese Journal of Cerebrovascular Diseases
基金 国家自然科学基金资助项目(30500519)
关键词 人脐静脉内皮细胞 阿托伐他汀 白细胞介素-6 细胞增殖 超微结构 Human umbilical vein cells Atorvastatin Interleukin-6 Proliferation Uhrastructure
  • 相关文献

参考文献8

  • 1[1]Ng CK,Chan AP,Cheng A.Impairment of endothelial function-A possible mechanism for atherosclerosis of a high-fat meal intake.Ann Acad Med Sigapore,2001,30:499-502.
  • 2[2]Bustos C,Hernandez-Presa MA,Ortego M,et al.HMGCoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.J Am Coll Cardiol,1998,32:2057-2064.
  • 3[3]Schonbeck U,Libby P.Inflammation,immunity,and HMG-CoA reductase inhibitors:statins as antiinflammatory agents? Circulation,2004,109 (21 Suppl 1):Ⅱ18-Ⅱ26.
  • 4[4]Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation,2002,105:1135-1143.
  • 5[5]Willerson JT,Ridker PM.Inflammation as a cardiovascular risk factor.Circulation,2004,109 (21 Suppl 1):Ⅱ 2-Ⅱ10.
  • 6凌锋,焦力群,代表国家"十五"医学攻关脑卒中规范化外科治疗技术推广应用研究课题组.颈动脉内膜剥脱术与支架成形术对颈动脉粥样硬化性狭窄治疗的初步研究[J].中国脑血管病杂志,2006,3(1):4-8. 被引量:61
  • 7[7]Hwang SJ,Ballantyne CM,Sharrett AR,et al.Circulating adhesion molecules VCAM-1,ICAM-1,and E-selectin in carotid atherosclerosis and incident coronary heart disease cases.The Atherosclerosis Risk in Communities (ARIC)study.Circulation,1997,96:4219-4225.
  • 8[8]Lowe GD,Rumley AD,McMahon AD,et al.West of Scotland Coronary Prevention Study.Interleukin-6,fibrin D-dimer,and coagulation factors Ⅶ and Ⅻa in prediction of coronary heart disease.Arterioscler Thromb Vasc Biol,2004,24:1529-1534.

二级参考文献19

  • 1[1]Jordan WD Jr,Schroeder PT,Fisher WS,et al.A comparison of angioplasty with stenting versus endarterectomy for the treatment of carotid artery stenosis.Ann Vasc Surg,1997,11:2-8.
  • 2[2]Jordan WD Jr,Voellinger DC,Doblar DD,et al.Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy.Cardiovasc Surg,1999,7:33-38.
  • 3[3]Poppert H,Wolf O,Resch M,et al.Differences in number,size and location of intracranial microembolic lesions after surgical versus endovascular treatment without protection device of carotid artery stenosis.J Neurol,2004,251:1198-1203.
  • 4[4]Mericle RA,Kim SH,Lanzino G,et al.Carotid artery angioplasty and use of stents in high-risk patients with contralateral occlusions.J Neurosurg,1999,90:1031-1036.
  • 5[5]Hobson RW,GoldsteinJE,Jamil Z,et al.Carotid restenosis:operative and endovascular management.J Vasc Surg,1999,29:228-235.
  • 6[6]Aburahma F,Bates MC,Stone PA,et al.Comparative study of operative treatment and percutaneous transluminal angioplasty/stenting for recurrent carotid disease.J Vasc Surg,2001,34:831-838.
  • 7[7]Jordan WD Jr,Alcocer F,Wirthlin DJ,et al.High-risk carotid endarterectomy:challenges for carotid stent protocols.J Vasc Surg,2002,35:16-21.
  • 8[8]Illig KA,Zhang R,Tanski W,et al.Is the rationale for carotid angioplasty and stenting in patients excluded from NASCET/ACAS or eligible for ARCHeR justified.? J Vasc Surg,2003,37:575-581.
  • 9[9]Kasirajan K,Matteson B,Marek JM,et al.Comparison of nonneurological events in high-risk patients treated by carotid angioplasty versus endarterectomy.Am J Surg,2003,185:301-304.
  • 10[10]Bowser N,Bandyk DF,Evans A,et al.Outcome of carotid stent-assisted angioplasty versus open surgical repair of recurrent carotid stenosis.J Vasc Surg,2003,38:432-438.

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部